Literature DB >> 7617864

Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions.

P R Ros1, P C Freeny, S E Harms, S E Seltzer, P L Davis, T W Chan, A E Stillman, L R Muroff, V M Runge, M A Nissenbaum.   

Abstract

PURPOSE: To assess the safety and diagnostic efficacy of intravenous ferumoxides, a superparamagnetic iron oxide, for depiction of focal hepatic lesions on magnetic resonance (MR) images.
MATERIALS AND METHODS: This open-label study included 208 patients with known or suspected focal hepatic lesions. MR images were obtained before and 45 minutes to 4 hours after intravenous infusion of ferumoxides (10 mumol/kg). The effect of ferumoxides on signal intensity of the liver was assessed with quantitative analysis. Safety was evaluated with patient monitoring and laboratory measurements.
RESULTS: Mean lesion-to-liver contrast-to-noise ratio on T2-weighted images was 9.1 on unenhanced images and 12.7 on enhanced images. Signal intensity of normal liver on enhanced images decreased to 37% of that on unenhanced images. In blinded image evaluations, additional lesions were identified on 27% of enhanced images. No serious adverse events occurred.
CONCLUSION: Ferumoxides is a safe and efficacious contrast agent for the detection of focal liver lesions on T2-weighted images.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7617864     DOI: 10.1148/radiology.196.2.7617864

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  39 in total

Review 1.  Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

Authors:  Nazila Kamaly; Zeyu Xiao; Pedro M Valencia; Aleksandar F Radovic-Moreno; Omid C Farokhzad
Journal:  Chem Soc Rev       Date:  2012-03-05       Impact factor: 54.564

2.  In vivo clearance and toxicity of monodisperse iron oxide nanocrystals.

Authors:  Luo Gu; Ronnie H Fang; Michael J Sailor; Ji-Ho Park
Journal:  ACS Nano       Date:  2012-06-05       Impact factor: 15.881

Review 3.  Safety of MR liver specific contrast media.

Authors:  Marie-France Bellin; Judith A W Webb; Aart J Van Der Molen; Henrik S Thomsen; Sameh K Morcos
Journal:  Eur Radiol       Date:  2004-12-31       Impact factor: 5.315

Review 4.  Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases.

Authors:  Howard E Gendelman; Vellareddy Anantharam; Tatiana Bronich; Shivani Ghaisas; Huajun Jin; Anumantha G Kanthasamy; Xinming Liu; JoEllyn McMillan; R Lee Mosley; Balaji Narasimhan; Surya K Mallapragada
Journal:  Nanomedicine       Date:  2015-01-31       Impact factor: 5.307

5.  Improved characterization of focal liver lesions with liver-specific gadoxetic acid disodium-enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial.

Authors:  Steven S Raman; Christopher Leary; David A Bluemke; Marco Amendola; Dushyant Sahani; Jeffrey D McTavish; Jeffrey Brody; Eric Outwater; Donald Mitchell; Douglas H Sheafor; Jeff Fidler; Isaac R Francis; Richard C Semelka; Kohkan Shamsi; Simone Gschwend; David R Feldman; Josy Breuer
Journal:  J Comput Assist Tomogr       Date:  2010 Mar-Apr       Impact factor: 1.826

6.  Relaxivity of Ferumoxytol at 1.5 T and 3.0 T.

Authors:  Gesine Knobloch; Timothy Colgan; Curtis N Wiens; Xiaoke Wang; Tilman Schubert; Diego Hernando; Samir D Sharma; Scott B Reeder
Journal:  Invest Radiol       Date:  2018-05       Impact factor: 6.016

7.  Quantification and biodistribution of iron oxide nanoparticles in the primary clearance organs of mice using T1 contrast for heating.

Authors:  Jinjin Zhang; Hattie L Ring; Katie R Hurley; Qi Shao; Cathy S Carlson; Djaudat Idiyatullin; Navid Manuchehrabadi; P Jack Hoopes; Christy L Haynes; John C Bischof; Michael Garwood
Journal:  Magn Reson Med       Date:  2016-09-25       Impact factor: 4.668

8.  Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application.

Authors:  Yi-Xiang J Wang
Journal:  Quant Imaging Med Surg       Date:  2011-12

Review 9.  Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions.

Authors:  Ahmed Ba-Ssalamah; Martin Uffmann; Sanjai Saini; Nina Bastati; Christian Herold; Wolfgang Schima
Journal:  Eur Radiol       Date:  2008-09-23       Impact factor: 5.315

10.  Ferucarbotran versus Gd-DTPA-enhanced MR imaging in the detection of focal hepatic lesions.

Authors:  Wei-Zhong Cheng; Meng-Su Zeng; Fu-Hua Yan; Shen-Xiang Rao; Ji-Zhang Shen; Cai-Zhong Chen; Shu-Jie Zhang; Wei-Bin Shi
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.